HONG KONG -- (Marketwire) -- 10/19/11 -- Today, www.WorldStreetFundamentals.com released its industry report highlighting Callon Petroleum Company (NYSE: CPE) and Halozyme Therapeutics, Inc. (NASDAQ: HALO). Full fundamental and technical analysis is available at www.WorldStreetFundamentals.com/Reports.php?id=CPE+HALO.
Short-term outlooks within US and global economies continue to adjust downward, as US Treasury yields touched their lowest levels in over 65 years. International Monetary Fund downgraded estimates for US growth by 1.0% this year, down from 2.5%. 'Significant downside risks' to the US economy were confirmed by the Federal Reserve pressured by 'strains in global financial markets.'
As the US dollar trades above an eight-month high against the Euro, it highlights a deepening of the Eurozone sovereign debt crisis -- furthered by continued policy inaction from European governments. We expect continued volatility until economic data stabilizes and we see decisive policy action to deal with the Eurozone debt crisis.
Our members are preparing for a turn in tides. Currently, the Credit Suisse Risk Appetite Indicator is at a 30-year low. For the past three occurrences, this level has acted as a leading indicator of large stock market rallies 18 months following.
World Street Fundamentals has highlighted Callon Petroleum Company for its current position within the basic materials industry. Callon Petroleum Company (Callon) is engaged in the exploration, development, acquisition and production of oil and gas properties. In September 2009, the Company acquired a 70% working interest in a 577-acre unit in the heart of the Haynesville Shale play in Bossier Parish, Louisiana. The entire report on Callon Petroleum Company (NYSE: CPE) is available here: www.WorldStreetFundamentals.com/Report.php?id=CPE.
World Street has featured Halozyme Therapeutics, Inc. for its development within the healthcare industry. Halozyme Therapeutics, Inc. (Halozyme) is a biopharmaceutical company. The Company is engaged in the development and commercialization of recombinant human enzymes, which either transiently modify tissue under the skin to facilitate injection of other therapies or correct diseased tissue structures for clinical benefit. The entire report on Halozyme Therapeutics, Inc. (NASDAQ: HALO) is available here: www.WorldStreetFundamentals.com/Report.php?id=HALO.
About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets.